Parsa Mehraban Far

A 57-year-old woman without a history of connective tissue disorders started dupilumab (initial dose 600 mg) for atopic dermatitis. Ocular history was noncontributory, and the patient had undergone a normal eye examination recently. Ten days later, she developed bilateral ocular pain.

ABSTRACT Purpose We describe a case vision-threatening sclerouveitis as a probable adverse drug reaction to ibrutinib. Results Ibrutinib is an inhibitor of Bruton's kinase which has shown success in the treatment of hematological malignancies such as chronic lymphocytic leukemia. Despite being generally well tolerated, recent studies have implicated ibrutinib in several adverse events affecting organs such as the heart, intestines, and the eyes.